Background The long time to diagnosis of medulloblastoma, one of the most frequent brain tumors in children, is the source of painful remorse and sometimes lawsuits. We analyzed its consequences for tumor stage, survival, and sequelae. Patients and Methods This retrospective population-based cohort study included all cases of pediatric medulloblastoma from a region of France between 1990 and 2005. We collected the demographic, clinical, and tumor data and analyzed the relations between the interval from symptom onset until diagnosis, initial disease stage, survival, and neuropsychological and neurological outcome. Results The median interval from symptom onset until diagnosis for the 166 cases was 65 days (interquartile range 31–121, range 3–457). A long interval (defined as longer than the median) was associated with a lower frequency of metastasis in the univariate and multivariate analyses and with a larger tumor volume, desmoplastic histology, and longer survival in the univariate analysis, but not after adjustment for confounding factors. The time to diagnosis was significantly associated with IQ score among survivors. No significant relation was found between the time to diagnosis and neurological disability. In the 62 patients with metastases, a long prediagnosis interval was associated with a higher T stage, infiltration of the fourth ventricle floor, and incomplete surgical resection; it nonetheless did not influence survival significantly in this subgroup. Conclusions We found complex and often inverse relations between time to diagnosis of medulloblastoma in children and initial severity factors, survival, and neuropsychological and neurological outcome. This interval appears due more to the nature of the tumor and its progression than to parental or medical factors. These conclusions should be taken into account in the information provided to parents and in expert assessments produced for malpractice claims.
References
[1]
Desandes E, Clavel J, Berger C, Bernard JL, Blouin P, et al. (2004) Cancer incidence among children in France, 1990–1999. Pediatr Blood Cancer 43: 749–757.
[2]
Desandes E, Berger C, Tron I, Demeocq F, Bellec S, et al. (2008) Childhood cancer survival in France, 1990–1999. Eur J Cancer 44: 205–215.
[3]
Verlooy J, Mosseri V, Bracard S, Tubiana AL, Kalifa C, et al. (2006) Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 42: 3004–3014.
[4]
Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, et al. (2005) Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6: 573–580.
[5]
Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, et al. (2005) Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 23: 4726–4734.
[6]
Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois C, et al. (1999) Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 45: 137–145.
[7]
Frange P, Alapetite C, Gaboriaud G, Bours D, Zucker JM, et al. (2009) From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000). J Neurooncol 95: 271–279.
[8]
Reulecke BC, Erker CG, Fiedler BJ, Niederstadt TU, Kurlemann G (2008) Brain tumors in children: initial symptoms and their influence on the time span between symptom onset and diagnosis. J Child Neurol 23: 178–183.
[9]
Haimi M, Peretz Nahum M, Ben Arush MW (2004) Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr Hematol Oncol 21: 37–48.
[10]
Pollock BH, Krischer JP, Vietti TJ (1991) Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr 119: 725–732.
[11]
Saha V, Love S, Eden T, Micallef-Eynaud P, MacKinlay G (1993) Determinants of symptom interval in childhood cancer. Arch Dis Child 68: 771–774.
[12]
Thulesius H, Pola J, Hakansson A (2000) Diagnostic delay in pediatric malignancies–a population-based study. Acta Oncol 39: 873–876.
[13]
Halperin EC, Watson DM, George SL (2001) Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma. Cancer 91: 1444–1450.
[14]
Flores LE, Williams DL, Bell BA, O'Brien M, Ragab AH (1986) Delay in the diagnosis of pediatric brain tumors. Am J Dis Child 140: 684–686.
[15]
Dobrovoljac M, Hengartner H, Boltshauser E, Grotzer MA (2002) Delay in the diagnosis of paediatric brain tumours. Eur J Pediatr 161: 663–667.
[16]
Mehta V, Chapman A, McNeely PD, Walling S, Howes WJ (2002) Latency between symptom onset and diagnosis of pediatric brain tumors: an Eastern Canadian geographic study. Neurosurgery 51: 365–372; discussion 372–363.
[17]
Kukal K, Dobrovoljac M, Boltshauser E, Ammann RA, Grotzer MA (2009) Does diagnostic delay result in decreased survival in paediatric brain tumours? Eur J Pediatr 168: 303–310.
[18]
Dang-Tan T, Franco EL (2007) Diagnosis delays in childhood cancer: a review. Cancer 110: 703–713.
[19]
Wilne SH, Ferris RC, Nathwani A, Kennedy CR (2006) The presenting features of brain tumours: a review of 200 cases. Arch Dis Child 91: 502–506.
[20]
Keene DL, Hsu E, Ventureyra E (1999) Brain tumors in childhood and adolescence. Pediatr Neurol 20: 198–203.
[21]
Loh AH, Ha C, Chua JH, Seow WT, Chan MY, et al. (2009) Delays in diagnosis of pediatric solid tumors in Singapore. J Pediatr Hematol Oncol 31: 734–738.
[22]
Klein-Geltink J, Pogany L, Mery LS, Barr RD, Greenberg ML (2006) Impact of age and diagnosis on waiting times between important healthcare events among children 0 to 19 years cared for in pediatric units: the Canadian Childhood Cancer Surveillance and Control Program. J Pediatr Hematol Oncol 28: 433–439.
[23]
Edgeworth J, Bullock P, Bailey A, Gallagher A, Crouchman M (1996) Why are brain tumours still being missed? Arch Dis Child 74: 148–151.
[24]
Dang-Tan T, Trottier H, Mery LS, Morrison HI, Barr RD, et al. (2008) Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer 51: 468–474.
[25]
Brasme JF, Chalumeau M, Doz F, Lacour B, Valteau-Couanet D, et al. (2011) Interval between onset of symptoms and diagnosis of medulloblastoma in children: distribution and determinants in a population-based study. Eur J Pediatr 171: 25–32.
[26]
Dixon-Woods M, Findlay M, Young B, Cox H, Heney D (2001) Parents' accounts of obtaining a diagnosis of childhood cancer. Lancet 357: 670–674.
[27]
Hoven E, Anclair M, Samuelsson U, Kogner P, Boman KK (2008) The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol 30: 807–814.
[28]
Najaf-Zadeh A, Dubos F, Pruvost I, Bons-Letouzey C, Amalberti R, et al. (2010) Epidemiology and aetiology of paediatric malpractice claims in France. Arch Dis Child 96: 127–130.
[29]
Sommelet D, Clavel J, Lacour B (2005) [Contribution of national paediatric cancer registries to survey and research]. Arch Pediatr 12: 814–816.
[30]
Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, et al. (2010) Incidence of childhood cancer in France: National Children Cancer Registries, 2000–2004. Eur J Cancer Prev 19: 173–181.
[31]
Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3: 255–268.
[32]
Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88: 2887.
[33]
Chang CH, Housepian EM, Herbert C Jr (1969) An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93: 1351–1359.
[34]
Harisiadis L, Chang CH (1977) Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2: 833–841.
[35]
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, et al. (2010) HIT - SIOP PNET4- A randomised multicentre study of hyperfractionated versus standard radiotherapy in children with standard risk medulloblastoma. Pediatr Blood Cancer 55: abstract O78.
[36]
Dufour C, Couanet D, Figarella-Branger D, Carrie C, Doz F, et al. (2008) Sequential high-dose chemotherapy with autologous stem cell rescue for children with high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Neuro-Oncology 10: 488 (abstract).
[37]
Dufour C, Couanet D, Figarella-Branger D, Carrie C, Doz F, et al. (2008) Sequential high-dose chemotherapy and reducued craniospinal irradiation in young children with metastatic medulloblastoma. Neuro-Oncology 10: 423 (abstract).
[38]
D'Agostino RB Jr (2007) Propensity scores in cardiovascular research. Circulation 115: 2340–2343.
[39]
Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, et al. (2011) Medulloblastoma Comprises Four Distinct Molecular Variants. J Clin Oncol: 29(11): 1408–1414.
[40]
Alston RD, Newton R, Kelsey A, Newbould MJ, Birch JM, et al. (2003) Childhood medulloblastoma in northwest England 1954 to 1997: incidence and survival. Dev Med Child Neurol 45: 308–314.
